Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|January 11, 2011
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidenceC Gridelli, F De Marinis, M Di Maio, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2011
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issuesC Gridelli, F De Marinis, M Di Maio, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|July 1, 1997
Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized studyF Bozzetti, L Biganzoli, C Gavazzi, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2008
Radiotherapy for small-cell lung cancer-Where are we heading?N A Bayman, H Sheikh, B Kularatne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2011
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyB Coudert, T Ciuleanu, K Park, et al.
Oncology|November 1, 1995
Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancerC Noberasco, E Bajetta, N Zilembo, et al.
ESMO Open|April 30, 2022
Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancerN Tinsley, C Zhou, S Nahm, et al.
British Journal of Cancer|July 31, 2008
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancerS Baka, R Califano, R Ferraldeschi, et al.
Journal of Endocrinological Investigation|March 23, 2024
Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumorsA La Salvia, B Marcozzi, C Manai, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
Pageof 9